CEO Spotlight: Jon Rees, CEO of MitoRx Therapeutics
About Jon Rees and MitoRx Therapeutics: • MitoRx is a preclinical research stage biotechnology...
read more
Midven has been working with Harwell Capital since 2012 transacting investments into technology companies on their behalf. Harwell’s funding comes from an extensive overseas network of private investors who are seeking access to technology investment opportunities from across the UK.
The Harwell Capital funding is appropriate for UK technology businesses with high growth potential seeking to raise between £500k and £5m. At the higher end of this investment range Harwell will likely participate as part of a consortium.
Midven are actively seeking new investment opportunities for Harwell Capital.
The investment team working with Harwell Capital is lead by Roger Wood.
